Departure of Directors or Certain

On January 23, 2021, Allena Pharmaceuticals, Inc. (the “Company”)
adopted the Allena Pharmaceuticals, Inc. 2021 Inducement Equity Plan (the “Inducement Plan”), pursuant to which the Company reserved 1,600,000 shares of its common stock for issuance under the Inducement Plan to be used exclusively for
grants of awards to individuals who were not previously employees of the Company, as an inducement material to the individual’s entry into employment with the Company within the meaning of Nasdaq Listing Rule 5635(c)(4). The Inducement Plan was
approved by the Board of Directors of the Company without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

The foregoing description of
the terms of the Inducement Plan is not intended to be complete and is qual ified in its entirety by reference to the Inducement Plan, a copy of which is included hereto as Exhibit 10.1 and incorporated herein by reference.

Exhibit 9.01 Financial Statements and Exhibits.



Exhibit No.





Allena Pharmaceuticals, Inc. 2021 Inducement Equity Plan


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.


Date: January 28, 2021



Allena Pharmaceuticals, Inc.





/s/ Edward Wholihan




Edward Wholihan




Chief Financial Officer

makes a similar move, sign up!

Other recent filings from the company include the following:

Statement of acquisition of beneficial ownership by individuals - Jan. 25, 2022
Allena Pharmaceuticals Provides Clinical And Corporate Update ALLN-346, - Jan. 4, 2022

Auto Refresh